WALTHAM, MA--(Marketwire - August 29, 2007) - EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced the appointment of Paul G. Chaney as a member of the Board of Directors. Mr. Chaney is Executive Vice President of OSI Pharmaceuticals (NASDAQ: OSIP) and President of (OSI) Eyetech, OSI’s eyecare subsidiary. Prior to the merger of Eyetech with OSI, Mr. Chaney served as Chief Operating Officer of Eyetech.
